A hereditary bleeding disorder resulting from a premature stop codon in thrombomodulin (p.Cys537Stop).

In this study, we describe a novel thrombomodulin (TM) mutation (c.1611C>A) that codes for a change from cysteine 537 to a premature stop codon (p.Cys537Stop). Three members of a family with a history of posttraumatic bleeding were identified to be heterozygous for this TM mutation. All coagulation screening tests, coagulation factor assays, and platelet function test results were within normal limits. However, the endogenous thrombin potential was markedly reduced at low-tissue factor concentration, and failure to correct with normal plasma indicated the presence of a coagulation inhibitor. Plasma TM levels were highly elevated (433-845 ng/ml, normal range 2-8 ng/ml, equating to 5 to 10 nM), and the addition of exogenous protein C further decreased thrombin generation. The mutation, p.Cys537Stop, results in a truncation within the carboxyl-terminal transmembrane helix. We predict that as a consequence of the truncation, the variant TM is shed from the endothelial surface into the blood plasma. This would promote systemic protein C activation and early cessation of thrombin generation within a developing hemostatic clot, thereby explaining the phenotype of posttraumatic bleeding observed within this family.

[1]  P. Reitsma,et al.  New fundamentals in hemostasis. , 2013, Physiological reviews.

[2]  T. Baglin,et al.  Evaluation of a standardized protocol for thrombin generation measurement using the calibrated automated thrombogram: an international multicentre study. , 2012, Thrombosis research.

[3]  Hua-Lin Wu,et al.  Thrombomodulin is an ezrin‐interacting protein that controls epithelial morphology and promotes collective cell migration , 2012, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[4]  J. Griffin,et al.  Protein C anticoagulant and cytoprotective pathways , 2012, International Journal of Hematology.

[5]  Z. Koncz,et al.  Thrombomodulin-dependent effect of factor VLeiden mutation on factor XIII activation. , 2012, Thrombosis research.

[6]  E. D. Candia,et al.  Mechanisms of platelet activation by thrombin: A short history , 2012 .

[7]  M. Shimaoka,et al.  Thrombomodulin: A Bifunctional Modulator of Inflammation and Coagulation in Sepsis , 2012, Critical care research and practice.

[8]  C. Esmon Protein C anticoagulant system—anti-inflammatory effects , 2011, Seminars in Immunopathology.

[9]  I. Maruyama,et al.  Thrombomodulin: protectorate God of the vasculature in thrombosis and inflammation , 2011, Journal of thrombosis and haemostasis : JTH.

[10]  J. Stockman Thrombomodulin Mutations in Atypical Hemolytic–Uremic Syndrome , 2011 .

[11]  L. O. Mosnier,et al.  Platelet Factor 4 Inhibits Thrombomodulin-dependent Activation of Thrombin-activatable Fibrinolysis Inhibitor (TAFI) by Thrombin* , 2010, The Journal of Biological Chemistry.

[12]  A. Rezaie Regulation of the protein C anticoagulant and antiinflammatory pathways. , 2010, Current medicinal chemistry.

[13]  D. Lane,et al.  The central role of thrombin in hemostasis , 2007, Journal of thrombosis and haemostasis : JTH.

[14]  J. Huntington,et al.  Thrombin-Cofactor Interactions: Structural Insights Into Regulatory Mechanisms , 2006, Arteriosclerosis, thrombosis, and vascular biology.

[15]  C. Esmon,et al.  Inflammation and the activated protein C anticoagulant pathway. , 2006, Seminars in thrombosis and hemostasis.

[16]  B. Bouma,et al.  Regulation of Fibrinolysis by Thrombin Activatable Fibrinolysis Inhibitor, an Unstable Carboxypeptidase B That Unites the Pathways of Coagulation and Fibrinolysis , 2001, Arteriosclerosis, thrombosis, and vascular biology.

[17]  Lawrence Leung,et al.  Roles of Low Specificity and Cofactor Interaction Sites on Thrombin during Factor XIII Activation , 2003, Journal of Biological Chemistry.

[18]  A. Folsom,et al.  Prospective study of the A455V polymorphism in the thrombomodulin gene, plasma thrombomodulin, and incidence of venous thromboembolism: the LITE Study , 2003, Journal of thrombosis and haemostasis : JTH.

[19]  E. Boerwinkle,et al.  Thrombomodulin Ala455Val Polymorphism and Risk of Coronary Heart Disease , 2001, Circulation.

[20]  B. Furie,et al.  Role of phosphatidylethanolamine in assembly and function of the factor IXa-factor VIIIa complex on membrane surfaces. , 2000, Biochemistry.

[21]  J. Morser,et al.  TAFI, or Plasma Procarboxypeptidase B, Couples the Coagulation and Fibrinolytic Cascades through the Thrombin-Thrombomodulin Complex* , 1996, The Journal of Biological Chemistry.

[22]  C. Vlahos,et al.  Stable expression of a secretable deletion mutant of recombinant human thrombomodulin in mammalian cells. , 1990, The Journal of biological chemistry.

[23]  C. Esmon,et al.  Complex formation between thrombin and thrombomodulin inhibits both thrombin-catalyzed fibrin formation and factor V activation. , 1982, The Journal of biological chemistry.

[24]  J. Giddings,et al.  Familial Haemostatic Defect Associated with Reduced Prothrombin Consumption , 1980, British journal of haematology.